Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 2Specimen Handling 2Nivolumab 2Biopsy 2talimogene laherparepvec 1mogamulizumab 1fludarabine phosphate 1fludarabine 1duvelisib 1durvalumab 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Sirolimus 1Radiotherapy 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunoglobulin G 1Gemcitabine 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Etoposide 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sezary Syndrome × duvelisib × Clear all
NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

National Cancer Institute (NCI)

Phase 1 Active not recruiting
38 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡